Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Joyce S Plested

Showing results (21-30 of 50) with videos related to

Pageof 5
Sort By:
Human Vaccines & Immunotherapeutics|July 2, 2026
Safety and immunogenicity of a COVID-19-Influenza Combination nanoparticle vaccine (CIC) containing SARS-CoV-2 recombinant spike and quadrivalent influenza hemagglutinin with Matrix-M® adjuvant: A phase 1/2 clinical trialVivek Shinde, Wayne Woo, Anthony M Marchese, et al.
Molecular Microbiology|April 4, 2002
Identification of a gene (lpt-3) required for the addition of phosphoethanolamine to the lipopolysaccharide inner core of Neisseria meningitidis and its role in mediating susceptibility to bactericidal killing and opsonophagocytosisFiona G Mackinnon, Andrew D Cox, Joyce S Plested, et al.
The Journal of Infectious Diseases|May 21, 2023
Strong CD4+ T-Cell Responses to Ancestral and Variant Spike Proteins Are Established by NVX-CoV2373 Severe Acute Respiratory Syndrome Coronavirus 2 Primary VaccinationLouis Fries, Neil Formica, Raburn M Mallory, et al.
Microorganisms|July 29, 2023
A Severe Acute Respiratory Syndrome Coronavirus 2 Anti-Spike Immunoglobulin G Assay: A Robust Method for Evaluation of Vaccine Immunogenicity Using an Established Correlate of ProtectionMingzhu Zhu, Shane Cloney-Clark, Sheau-Line Feng, et al.
Microorganisms|May 27, 2026
Validation of a Pseudovirus Neutralization Assay for Severe Acute Respiratory Syndrome Coronavirus 2 Omicron JN.1 and LP.8.1 Subvariant Lineage Strains with Homologous and Heterologous Matched Sera in Clinically Relevant SamplesZhaohui Cai, Raj Kalkeri, Benjamin Haner, et al.
The Journal of Biological Chemistry|October 4, 2003
Neisserial lipooligosaccharide is a target for complement component C4b. Inner core phosphoethanolamine residues define C4b linkage specificitySanjay Ram, Andrew D Cox, J Claire Wright, et al.
The Lancet. Infectious Diseases|January 17, 2025
Immunogenicity and safety of a monovalent omicron XBB.1.5 SARS-CoV-2 recombinant spike protein vaccine as a heterologous booster dose in US adults: interim analysis of a single-arm phase 2/3 studyKatia Alves, Karen Kotloff, R Scott McClelland, et al.
Vaccine|June 4, 2023
Immunogenicity and safety of a fourth homologous dose of NVX-CoV2373Katia Alves, Joyce S Plested, Shirley Galbiati, et al.
The New England Journal of Medicine|February 3, 2023
Immunogenicity of a Fourth Homologous Dose of NVX-CoV2373Katia Alves, Joyce S Plested, Shirley Galbiati, et al.
Medrxiv : the Preprint Server for Health Sciences|January 31, 2024
Altered IgG4 Antibody Response to Repeated mRNA versus Protein COVID VaccinesRaj Kalkeri, Mingzhu Zhu, Shane Cloney-Clark, et al.
Pageof 5

Showing results (21-30 of 50) with videos related to

Sort By:
Pageof 5
Human Vaccines & Immunotherapeutics|July 2, 2026
Safety and immunogenicity of a COVID-19-Influenza Combination nanoparticle vaccine (CIC) containing SARS-CoV-2 recombinant spike and quadrivalent influenza hemagglutinin with Matrix-M® adjuvant: A phase 1/2 clinical trialVivek Shinde, Wayne Woo, Anthony M Marchese, et al.
Molecular Microbiology|April 4, 2002
Identification of a gene (lpt-3) required for the addition of phosphoethanolamine to the lipopolysaccharide inner core of Neisseria meningitidis and its role in mediating susceptibility to bactericidal killing and opsonophagocytosisFiona G Mackinnon, Andrew D Cox, Joyce S Plested, et al.
The Journal of Infectious Diseases|May 21, 2023
Strong CD4+ T-Cell Responses to Ancestral and Variant Spike Proteins Are Established by NVX-CoV2373 Severe Acute Respiratory Syndrome Coronavirus 2 Primary VaccinationLouis Fries, Neil Formica, Raburn M Mallory, et al.
Microorganisms|July 29, 2023
A Severe Acute Respiratory Syndrome Coronavirus 2 Anti-Spike Immunoglobulin G Assay: A Robust Method for Evaluation of Vaccine Immunogenicity Using an Established Correlate of ProtectionMingzhu Zhu, Shane Cloney-Clark, Sheau-Line Feng, et al.
Microorganisms|May 27, 2026
Validation of a Pseudovirus Neutralization Assay for Severe Acute Respiratory Syndrome Coronavirus 2 Omicron JN.1 and LP.8.1 Subvariant Lineage Strains with Homologous and Heterologous Matched Sera in Clinically Relevant SamplesZhaohui Cai, Raj Kalkeri, Benjamin Haner, et al.
The Journal of Biological Chemistry|October 4, 2003
Neisserial lipooligosaccharide is a target for complement component C4b. Inner core phosphoethanolamine residues define C4b linkage specificitySanjay Ram, Andrew D Cox, J Claire Wright, et al.
The Lancet. Infectious Diseases|January 17, 2025
Immunogenicity and safety of a monovalent omicron XBB.1.5 SARS-CoV-2 recombinant spike protein vaccine as a heterologous booster dose in US adults: interim analysis of a single-arm phase 2/3 studyKatia Alves, Karen Kotloff, R Scott McClelland, et al.
Vaccine|June 4, 2023
Immunogenicity and safety of a fourth homologous dose of NVX-CoV2373Katia Alves, Joyce S Plested, Shirley Galbiati, et al.
The New England Journal of Medicine|February 3, 2023
Immunogenicity of a Fourth Homologous Dose of NVX-CoV2373Katia Alves, Joyce S Plested, Shirley Galbiati, et al.
Medrxiv : the Preprint Server for Health Sciences|January 31, 2024
Altered IgG4 Antibody Response to Repeated mRNA versus Protein COVID VaccinesRaj Kalkeri, Mingzhu Zhu, Shane Cloney-Clark, et al.
Pageof 5